Castle Biosciences (CSTL) Depreciation & Amortization (CF) (2018 - 2026)

Castle Biosciences has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $4.1 million in Q2 2026.

• Quarterly Depreciation & Amortization (CF) rose 19.21% year-over-year to $4.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.6 million (down 63.3% YoY) and the FY2025 annual result came in at $40.8 million, up 154.87% from the prior year.
• Depreciation & Amortization (CF) grew to $4.1 million in Q2 2026 per CSTL's latest filing, from $3.9 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $29.8 million in Q1 2025 and troughed at $2.2 million in Q1 2022.
• A 5-year average of $4.9 million and a median of $3.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) surged 823.18% in 2022, then sank 86.8% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $2.8 million in 2022, then climbed by 13.48% to $3.2 million in 2023, then jumped by 78.91% to $5.8 million in 2024, then plunged by 34.52% to $3.8 million in 2025, then grew by 7.76% to $4.1 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4.1 million, $3.9 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.